JPS63152327A - 脂肪乳剤から成る溶血防止用組成物を含有する製剤 - Google Patents
脂肪乳剤から成る溶血防止用組成物を含有する製剤Info
- Publication number
- JPS63152327A JPS63152327A JP62293142A JP29314287A JPS63152327A JP S63152327 A JPS63152327 A JP S63152327A JP 62293142 A JP62293142 A JP 62293142A JP 29314287 A JP29314287 A JP 29314287A JP S63152327 A JPS63152327 A JP S63152327A
- Authority
- JP
- Japan
- Prior art keywords
- fat emulsion
- anticancer agent
- lysophospholipids
- immunostimulant
- hemolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002960 lipid emulsion Substances 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 206010018910 Haemolysis Diseases 0.000 title claims abstract description 22
- 230000008588 hemolysis Effects 0.000 title claims abstract description 22
- 239000002246 antineoplastic agent Substances 0.000 title claims description 17
- 239000003795 chemical substances by application Substances 0.000 title abstract description 7
- 230000003213 activating effect Effects 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 18
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000011187 glycerol Nutrition 0.000 claims abstract description 9
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 8
- 230000003308 immunostimulating effect Effects 0.000 claims description 19
- 229960001438 immunostimulant agent Drugs 0.000 claims description 16
- 239000003022 immunostimulating agent Substances 0.000 claims description 16
- 239000003549 soybean oil Substances 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 6
- 239000008344 egg yolk phospholipid Substances 0.000 claims description 5
- 229940068998 egg yolk phospholipid Drugs 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- MHFRGQHAERHWKZ-UHFFFAOYSA-N 1-octadecyl-2-methylglycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000007924 injection Substances 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 7
- 238000001990 intravenous administration Methods 0.000 abstract description 4
- 229950004354 phosphorylcholine Drugs 0.000 abstract 1
- 230000002949 hemolytic effect Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 8
- 239000003708 ampul Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62293142A JPS63152327A (ja) | 1987-11-20 | 1987-11-20 | 脂肪乳剤から成る溶血防止用組成物を含有する製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62293142A JPS63152327A (ja) | 1987-11-20 | 1987-11-20 | 脂肪乳剤から成る溶血防止用組成物を含有する製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2460079A Division JPS55118419A (en) | 1979-03-05 | 1979-03-05 | Antihemolytic composition consisting of fat emulsion and immunizator and carcinostatic agent containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63152327A true JPS63152327A (ja) | 1988-06-24 |
| JPS6410499B2 JPS6410499B2 (nl) | 1989-02-22 |
Family
ID=17790967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62293142A Granted JPS63152327A (ja) | 1987-11-20 | 1987-11-20 | 脂肪乳剤から成る溶血防止用組成物を含有する製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63152327A (nl) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277888B1 (en) | 1997-02-27 | 2001-08-21 | Welfide Corporation | Drug composition |
| JP2002513773A (ja) * | 1998-05-07 | 2002-05-14 | コリクサ コーポレイション | アジュバント組成物及びその使用法 |
| JP2007176868A (ja) * | 2005-12-28 | 2007-07-12 | Nagase Chemtex Corp | β−グルクロニダーゼ阻害剤 |
| KR100842159B1 (ko) | 2002-03-25 | 2008-06-27 | 주식회사 바이오시너젠 | 라이소포스파티딜콜린 또는 그 유사체를 포함하는 급성호흡곤란 증후군 및 다발성 장기부전의 예방 및 치료용조성물 |
| KR100849448B1 (ko) * | 2002-08-22 | 2008-07-30 | 주식회사 바이오시너젠 | 라이소포스파티딜콜린 또는 그 유사체를 포함하는 선천성면역 증강 조성물 |
| WO2015152412A1 (ja) * | 2014-04-04 | 2015-10-08 | 国立大学法人大阪大学 | リゾリン脂質受容体を活性化する物質を含有する薬剤送達促進剤 |
| WO2017057643A1 (ja) * | 2015-09-29 | 2017-04-06 | 国立大学法人大阪大学 | 白血球浸潤促進剤および腫瘍免疫活性化剤 |
-
1987
- 1987-11-20 JP JP62293142A patent/JPS63152327A/ja active Granted
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277888B1 (en) | 1997-02-27 | 2001-08-21 | Welfide Corporation | Drug composition |
| EP2030614A1 (en) * | 1997-02-27 | 2009-03-04 | Novartis AG | Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin |
| JP2002513773A (ja) * | 1998-05-07 | 2002-05-14 | コリクサ コーポレイション | アジュバント組成物及びその使用法 |
| KR100842159B1 (ko) | 2002-03-25 | 2008-06-27 | 주식회사 바이오시너젠 | 라이소포스파티딜콜린 또는 그 유사체를 포함하는 급성호흡곤란 증후군 및 다발성 장기부전의 예방 및 치료용조성물 |
| KR100849448B1 (ko) * | 2002-08-22 | 2008-07-30 | 주식회사 바이오시너젠 | 라이소포스파티딜콜린 또는 그 유사체를 포함하는 선천성면역 증강 조성물 |
| JP2007176868A (ja) * | 2005-12-28 | 2007-07-12 | Nagase Chemtex Corp | β−グルクロニダーゼ阻害剤 |
| WO2015152412A1 (ja) * | 2014-04-04 | 2015-10-08 | 国立大学法人大阪大学 | リゾリン脂質受容体を活性化する物質を含有する薬剤送達促進剤 |
| JPWO2015152412A1 (ja) * | 2014-04-04 | 2017-04-13 | 国立大学法人大阪大学 | リゾリン脂質受容体を活性化する物質を含有する薬剤送達促進剤 |
| WO2017057643A1 (ja) * | 2015-09-29 | 2017-04-06 | 国立大学法人大阪大学 | 白血球浸潤促進剤および腫瘍免疫活性化剤 |
| CN108136020A (zh) * | 2015-09-29 | 2018-06-08 | 国立大学法人大阪大学 | 白细胞浸润促进剂和肿瘤免疫活化剂 |
| JPWO2017057643A1 (ja) * | 2015-09-29 | 2018-08-16 | 国立大学法人大阪大学 | 白血球浸潤促進剤および腫瘍免疫活性化剤 |
| AU2016329670B2 (en) * | 2015-09-29 | 2019-12-12 | Osaka University | Leukocyte infiltration promoting agent and antitumor immunostimulatory agent |
| JP2020073572A (ja) * | 2015-09-29 | 2020-05-14 | 国立大学法人大阪大学 | 白血球浸潤促進剤および腫瘍免疫活性化剤 |
| US11033559B2 (en) | 2015-09-29 | 2021-06-15 | Osaka University | Leukocyte infiltration promoting agent and antitumor immunostimulatory agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6410499B2 (nl) | 1989-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI241914B (en) | Medicinal preparation containing lipophilic inert gas | |
| US20120329765A1 (en) | Medicinal targeted local lipolysis | |
| KR101951933B1 (ko) | 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법 | |
| ES2284900T3 (es) | Fosfatos micronutrientes como complementos dieteticos y para la salud. | |
| US20060241086A1 (en) | Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin | |
| West et al. | Use of cholestyramine in treatment of children with familial hypercholesterolaemia | |
| US7759332B2 (en) | Cytotropic heterogeneous molecular lipids (CHML), method of preparation, and methods of treating patients with multiple cancers | |
| WO2013151341A1 (en) | Injectable composition comprising phosphatidylcholine and method for preparing thereof | |
| JPS63152327A (ja) | 脂肪乳剤から成る溶血防止用組成物を含有する製剤 | |
| Byers et al. | Effect of infusions of phosphatides upon the atherosclerotic aorta in situ and as an ocular aortic implant | |
| AU2004285264A1 (en) | Medicamentously targeted local lipolysis | |
| WO1991017766A1 (en) | Remedy for asthma | |
| US3044931A (en) | Aryloxy acetic acid amides: process for parenteral application | |
| EP1558226A2 (en) | Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics | |
| JPS58162517A (ja) | 脂溶性ビタミン含有脂肪乳剤 | |
| JPS6410501B2 (nl) | ||
| BE881238A (nl) | Farmaceutisch preparaat en werkwijze ter bereiding daarvan | |
| CN105939706A (zh) | 用于肠胃外给药的包含epa乙酯和dha乙酯的组合物 | |
| CA2379815A1 (en) | Parenteral cisplatin emulsion | |
| JP3695499B2 (ja) | 脂肪乳剤 | |
| EP1973398A1 (en) | Use of inositol-tripyrophosphate in treating tumors and diseases | |
| EP0145873B1 (en) | Transfusion emulsion | |
| JP2003528134A (ja) | 白血球産生の刺激用および腫瘍および原虫症の治療用およびダニ症、節足動物媒介感染の治療用医薬組成物およびその製法 | |
| Schiff et al. | THROMBOCYTOSIS PRODUCED BY A HITHERTO UNKNOWN SUBSTANCE—THE FAT-SOLUBLE T FACTOR | |
| Helson | A Phase I study of vitamin E and neuroblastoma |